Major Depressive Disorder - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 201 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Major Depressive Disorder - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Major Depressive Disorder - Pipeline Review, H2 2016, provides an overview of the Major Depressive Disorder (Central Nervous System) pipeline landscape.

Major depressive disorder (MDD) is a mental disorder characterized by a pervasive and persistent low mood that is accompanied by low self-esteem and by a loss of interest or pleasure in normally enjoyable activities. Symptoms of MDD include agitation, restlessness, and irritability, anger, becoming withdrawn or isolated, fatigue and lack of energy, feeling hopeless and helpless, worthless, guilty, self-hate, loss of interest or pleasure in activities that were once enjoyed, sudden change in appetite, often with weight gain or loss, thoughts of death or suicide, trouble concentrating and trouble sleeping or sleeping too much. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Major Depressive Disorder - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Major Depressive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Major Depressive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 18, 11, 1, 8 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Major Depressive Disorder.

Major Depressive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Major Depressive Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Major Depressive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Major Depressive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Major Depressive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Major Depressive Disorder (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Major Depressive Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Major Depressive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 5
Major Depressive Disorder Overview 6
Therapeutics Development 7
Major Depressive Disorder - Therapeutics under Development by Companies 9
Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes 11
Major Depressive Disorder - Pipeline Products Glance 12
Major Depressive Disorder - Products under Development by Companies 15
Major Depressive Disorder - Products under Investigation by Universities/Institutes 18
Major Depressive Disorder - Companies Involved in Therapeutics Development 19
Major Depressive Disorder - Therapeutics Assessment 55
Drug Profiles 68
Major Depressive Disorder - Dormant Projects 174
Major Depressive Disorder - Discontinued Products 181
Major Depressive Disorder - Product Development Milestones 184
Appendix 194

List of Tables

Number of Products under Development for Major Depressive Disorder, H2 2016 13
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Late Stage Development, H2 2016 18
Comparative Analysis by Clinical Stage Development, H2 2016 19
Comparative Analysis by Early Stage Development, H2 2016 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2016 24
Major Depressive Disorder - Pipeline by Aequus Pharmaceuticals Inc., H2 2016 25
Major Depressive Disorder - Pipeline by Alkermes Plc, H2 2016 26
Major Depressive Disorder - Pipeline by Allergan Plc, H2 2016 27
Major Depressive Disorder - Pipeline by Angelini Group, H2 2016 28
Major Depressive Disorder - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016 29
Major Depressive Disorder - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 30
Major Depressive Disorder - Pipeline by BioCrea GmbH, H2 2016 31
Major Depressive Disorder - Pipeline by BioLite, Inc., H2 2016 32
Major Depressive Disorder - Pipeline by Bristol-Myers Squibb Company, H2 2016 33
Major Depressive Disorder - Pipeline by Cerecor Inc., H2 2016 34
Major Depressive Disorder - Pipeline by Clera Inc., H2 2016 35
Major Depressive Disorder - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016 36
Major Depressive Disorder - Pipeline by GlaxoSmithKline Plc, H2 2016 37
Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H2 2016 38
Major Depressive Disorder - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 39
Major Depressive Disorder - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 40
Major Depressive Disorder - Pipeline by Johnson & Johnson, H2 2016 41
Major Depressive Disorder - Pipeline by Lead Discovery Center GmbH, H2 2016 42
Major Depressive Disorder - Pipeline by Les Laboratoires Servier SAS, H2 2016 43
Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H2 2016 44
Major Depressive Disorder - Pipeline by Mapreg S.A.S., H2 2016 45
Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H2 2016 46
Major Depressive Disorder - Pipeline by miCure Therapeutics Ltd., H2 2016 47
Major Depressive Disorder - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 48
Major Depressive Disorder - Pipeline by Neuralstem, Inc., H2 2016 49
Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H2 2016 50
Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 51
Major Depressive Disorder - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016 52
Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 53
Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H2 2016 54
Major Depressive Disorder - Pipeline by Saniona AB, H2 2016 55
Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H2 2016 56
Major Depressive Disorder - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 57
Major Depressive Disorder - Pipeline by TRImaran Pharma, Inc., H2 2016 58
Major Depressive Disorder - Pipeline by Turing Pharmaceuticals AG , H2 2016 59
Major Depressive Disorder - Pipeline by VistaGen Therapeutics , Inc., H2 2016 60
Assessment by Monotherapy Products, H2 2016 61
Assessment by Combination Products, H2 2016 62
Number of Products by Stage and Target, H2 2016 64
Number of Products by Stage and Mechanism of Action, H2 2016 67
Number of Products by Stage and Route of Administration, H2 2016 71
Number of Products by Stage and Molecule Type, H2 2016 73
Major Depressive Disorder - Dormant Projects, H2 2016 180
Major Depressive Disorder - Dormant Projects (Contd..1), H2 2016 181
Major Depressive Disorder - Dormant Projects (Contd..2), H2 2016 182
Major Depressive Disorder - Dormant Projects (Contd..3), H2 2016 183
Major Depressive Disorder - Dormant Projects (Contd..4), H2 2016 184
Major Depressive Disorder - Dormant Projects (Contd..5), H2 2016 185
Major Depressive Disorder - Dormant Projects (Contd..6), H2 2016 186
Major Depressive Disorder - Discontinued Products, H2 2016 187
Major Depressive Disorder - Discontinued Products (Contd..1), H2 2016 188
Major Depressive Disorder - Discontinued Products (Contd..2), H2 2016 189